Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elsiglutide for Prevention of Chemotherapy Induced Diarrhea in Colorectal Cancer
NCT02383810Phase 2Completed
- Sponsor
- Helsinn
- Start
- Jan 2015
- Primary completion
- Feb 2016
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of elsiglutide in diarrhea (8 arms), sponsored by Helsinn. Primary endpoint: Proportion of Patients Experiencing a Maximum Grade >= 2 Diarrhea During the First Cycle of Chemotherapy in the Target Population at 15 days. Started Jan 2015; status: completed.
02
Drugs
elsiglutide
03
Conditions
diarrhea
Beyond the preview
Go deeper on NCT02383810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02383810.